Pain management, also termed as algiatry, is a branch of medicine that utilizes an interdisciplinary approach to ease and improve the quality of life of those suffering with pain. Pain is an ultimate result of trauma or tissue damage and the intensity of pain varies from person to person. Pain can be classified based on its occurrence and duration along with the affected body part. First line of treatment for pain management is pharmaceutical therapeutics or pain killer drugs, most of which are well known brands. The other pain management methods include physiotherapy, pain managing devices and chiropractor therapy. Research Beam Model: Research Beam Product ID: 21068 5370 USD New
Pain Management Drugs Market by Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Antimigraine Agents, Antidepressants, Opioids [Tramadol, Hydrocodone, Oxycodone, and Others], and Nonnarcotic Analgesics) and Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, and Fibromyalgia) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Toll Free : +1 (800)910-6452

 
 
PURCHASE OPTIONS
 

Pain Management Drugs Market by Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Antimigraine Agents, Antidepressants, Opioids [Tramadol, Hydrocodone, Oxycodone, and Others], and Nonnarcotic Analgesics) and Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, and Fibromyalgia) - Global Opportunity Analysis and Industry Forecast, 2017-2023

 
  • Category : Pharmaceuticals
  • Published On : October  2017
  • Pages : 170
 
 

Pain management is a branch of medicine, which employs approach to ease the suffering and improve the quality of life of individuals suffering from pain. Pain can be classified based on its occurrence and duration along with the affected body part. First line of treatment for pain management is pharmaceutical therapeutics or pain killer drugs, most of which are well-known brands. The global pain management drugs market was valued at $58,577 million in 2016, and is estimated to reach $77,131 million by 2023, registering a CAGR of 4% from 2017 to 2023.

Rise in geriatric population is the major factor that drives the growth of the global pain management market, as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth.

Furthermore, increase in number of surgical procedures and rise in healthcare expenditure are expected to fuel the growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.

The global pain management drugs market is segmented based on drug class, indication, and geography. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics. Opioids are further classified into tramadol, hydrocodone, oxycodone, and others (fentanyl, morphine, meperidine, codeine, and methadone). By indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, and fibromyalgia. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • This report offers a detailed quantitative analysis of the current & future market trends from 2016 to 2023 to identify the prevailing opportunities.
  • The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
  • The global pain management drugs market is comprehensively analyzed with respect to drug class, indication, and geography.
  • In-depth analysis based on geography facilitates to analyze the regional trends to assist in strategic business planning.
  • The developmental strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY PLAYERS PROFILED

  • Novartis AG
  • Eli Lilly & Company
  • Abbott Laboratories
  • Endo Health Solutions, Inc.
  • Purdue Pharma L.P.
  • Pfizer, Inc.
  • F. Hoffmann La Roche Ltd.
  • Merck & Co. Inc.
  • Johnson & Johnson
  • GlaxoSmithKline Plc.

KEY MARKET SEGMENTS

By Drug Class

  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Antimigraine Agents
  • Antidepressants
  • Opioids
    • Tramadol
    • Hydrocodone
    • Oxycodone
    • Others
  • Nonnarcotic Analgesics

By Indication

  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Postoperative Pain
  • Migraine
  • Fibromyalgia

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Republic of South Africa
    • Saudi Arabia
    • Rest of LAMEA

The other players operating in the pain management drugs market include (companies not profiled in the report):

  • Allergen Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • Valeant Pharmaceuticals International Inc.
  • Boehringer Ingelheim
  • Sorrento Therapeutics
  • WEX Pharmaceuticals
  • Zynerba Pharmaceuticals

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATION AND REIMBURSEMENT SCENARIO
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Favorable regulatory scenario
3.5.1.2. Increase in geriatric population
3.5.1.3. Rise in incidence of chronic diseases

3.5.2. Restraints

3.5.2.1. Availability of alternative therapies
3.5.2.2. Drug exploitation
3.5.2.3. Patent expiration of prescription drugs

3.5.3. Opportunities

3.5.3.1. Advancements in drug development
3.5.3.2. Untapped markets in developing economies

CHAPTER 4 PAIN MANAGEMENT DRUGS MARKET, BY DRUG TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. NSAIDS

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. ANESTHETICS

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. ANTICONVULSANTS

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

4.5. ANTI-MIGRAINE AGENTS

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

4.6. ANTIDEPRESSANTS

4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast

4.7. OPIOIDS

4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast
4.7.4. Tramadol
4.7.5. Hydrocodone
4.7.6. Oxycodaone
4.7.7. Others

4.8. NON-NARCOTIC ANALGESICS

4.8.1. Key market trends
4.8.2. Key growth factors and opportunities
4.8.3. Market size and forecast

CHAPTER 5 PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ARTHRITIC PAIN

5.2.1. Market size and forecast

5.3. NEUROPATHIC PAIN

5.3.1. Market size and forecast

5.4. CANCER PAIN

5.4.1. Market size and forecast

5.5. CHRONIC BACK PAIN

5.5.1. Market size and forecast

5.6. POST-OPERATIVE PAIN

5.6.1. Market size and forecast

5.7. MIGRAINE

5.7.1. Market size and forecast

5.8. FIBROMYALGIA

5.8.1. Market size and forecast

CHAPTER 6 PAIN MANAGEMENT DRUGS MARKET, BY GEOGRAPHY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast by country
6.2.4. Market size and forecast by drug class
6.2.5. Market size and forecast by indications

6.2.5.1. U.S. market size and forecast by drug class
6.2.5.2. U.S. market size and forecast by indication
6.2.5.3. Canada market size and forecast by drug class
6.2.5.4. Canada market size and forecast by indication
6.2.5.5. Mexico market size and forecast by drug class
6.2.5.6. Mexico market size and forecast by indication

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast by country
6.3.4. Market size and forecast by drug class
6.3.5. Market size and forecast by indication

6.3.5.1. UK market size and forecast by drug class
6.3.5.2. UK market size and forecast by indication
6.3.5.3. France market size and forecast by drug class
6.3.5.4. France market size and forecast by indication
6.3.5.5. Germany market size and forecast by drug class
6.3.5.6. Germany market size and forecast by indication
6.3.5.7. Italy market size and forecast by drug class
6.3.5.8. Italy market size and forecast by indication
6.3.5.9. Spain market size and forecast by drug class
6.3.5.10. Spain market size and forecast by indication
6.3.5.11. Rest of Europe market size and forecast by drug class
6.3.5.12. Rest of Europe market size and forecast by indication

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast by country
6.4.4. Market size and forecast by drug class
6.4.5. Market size and forecast by indications

6.4.5.1. Japan market size and forecast by drug class
6.4.5.2. Japan market size and forecast by indication
6.4.5.3. China market size and forecast by drug class
6.4.5.4. China market size and forecast by indication
6.4.5.5. Australia market size and forecast by drug class
6.4.5.6. Australia market size and forecast by indication
6.4.5.7. South Korea market size and forecast by drug class
6.4.5.8. South Korea market size and forecast by indication
6.4.5.9. India market size and forecast by drug class
6.4.5.10. India market size and forecast by indication
6.4.5.11. Taiwan market size and forecast by drug class
6.4.5.12. Taiwan market size and forecast by indication
6.4.5.13. Rest of Asia-Pacific market size and forecast by drug class
6.4.5.14. Rest of Asia-Pacific market size and forecast by indication

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast by country
6.5.4. Market size and forecast by drug class
6.5.5. Market size and forecast by indication

6.5.5.1. Brazil market size and forecast by drug class
6.5.5.2. Brazil market size and forecast by indication
6.5.5.3. South Africa market size and forecast by drug class
6.5.5.4. South Africa market size and forecast by indication
6.5.5.5. Saudi Arabia market size and forecast by drug class
6.5.5.6. Saudi Arabia market size and forecast by indication
6.5.5.7. Rest of LAMEA market size and forecast by drug class
6.5.5.8. Rest of LAMEA market size and forecast by indication

CHAPTER 7 COMPANY PROFILES

7.1. NOVARTIS AG

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Business performance
7.1.5. Key strategic moves and developments

7.2. ELI LILLY & COMPANY

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments

7.3. ABBOTT LABORATORIES, INC.

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key strategic moves and developments

7.4. ENDO HEALTH SOLUTIONS, INC.

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Business performance
7.4.5. Key strategic moves and developments

7.5. PURDUE PHARMA L.P.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.5.5. Key strategic moves and developments

7.6. PFIZER, INC.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Key strategic moves and developments

7.7. F. HOFFMANN LA ROCHE LTD.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance
7.7.5. Key strategic moves and developments

7.8. MERCK & CO. INC.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Key strategic moves and developments

7.9. JOHNSON & JOHNSON

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.9.5. Key strategic moves and developments

7.10. GLAXOSMITHKLINE PLC.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Business performance
7.10.5. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 2. PAIN MANAGEMENT DRUGS MARKET USING NSAIDS, BY REGION, 2016-2023 ($MILLION)
TABLE 3. PAIN MANAGEMENT DRUGS MARKET USING ANESTHETICS, BY REGION, 2016-2023 ($MILLION)
TABLE 4. PAIN MANAGEMENT DRUGS MARKET USING ANTICONVULSANTS, BY REGION, 2016-2023 ($MILLION)
TABLE 5. PAIN MANAGEMENT DRUGS MARKET USING ANTI-MIGRAINE AGENTS, BY REGION, 2016-2023 ($MILLION)
TABLE 6. PAIN MANAGEMENT DRUGS MARKET USING ANTIDEPRESSANTS, BY REGION, 2016-2023 ($MILLION)
TABLE 7. PAIN MANAGEMENT DRUGS MARKET USING OPIOIDS, BY REGION, 2016-2023 ($MILLION)
TABLE 8. PAIN MANAGEMENT DRUGS MARKET USING NON-NARCOTIC ANALGESICS, BY REGION, 2016-2023 ($MILLION)
TABLE 9. GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 10. PAIN MANAGEMENT DRUGS MARKET FOR ARTHRITIC PAIN, BY REGION, 2016-2023 ($MILLION)
TABLE 11. PAIN MANAGEMENT DRUGS MARKET FOR NEUROPATHIC PAIN, BY REGION, 2016-2023 ($MILLION)
TABLE 12. PAIN MANAGEMENT DRUGS MARKET FOR CANCER PAIN, BY REGION, 2016-2023 ($MILLION)
TABLE 13. PAIN MANAGEMENT DRUGS MARKET FOR CHRONIC BACK PAIN, BY REGION, 2016-2023 ($MILLION)
TABLE 14. PAIN MANAGEMENT DRUGS MARKET FOR POST-OPERATIVE PAIN, BY REGION, 2016-2023 ($MILLION)
TABLE 15. PAIN MANAGEMENT DRUGS MARKET FOR MIGRAINE, BY REGION, 2016-2023 ($MILLION)
TABLE 16. PAIN MANAGEMENT DRUGS MARKET FOR FIBROMYALGIA, BY REGION, 2016-2023 ($MILLION)
TABLE 17. PAIN MANAGEMENT DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 18. NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 19. NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 20. NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 21. U.S. PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 22. U.S. PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 23. CANADA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 24. CANADA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 25. MEXICO PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 26. MEXICO PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 27. EUROPE PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 28. EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 29. EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 30. UK PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 31. UK PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 32. FRANCE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 33. FRANCE PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 34. GERMANY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 35. GERMANY PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 36. ITALY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 37. ITALY PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 38. SPAIN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 39. SPAIN PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 40. REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 41. REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 42. ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 43. ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 44. ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 45. JAPAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 46. JAPAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 47. CHINA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 48. CHINA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 49. AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 50. AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 51. SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 52. SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 53. INDIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 54. INDIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 55. TAIWAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 56. TAIWAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 57. REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 58. REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 59. LAMEA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 60. LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 61. LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 62. BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 63. BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 64. SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 65. SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 66. SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 67. SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 68. REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 69. REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)

LIST OF FIGURES

FIGURE 1. SEGMENTATION OF GLOBAL PAIN MANAGEMENT DRUGS MARKET
FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL PAIN MANAGEMENT DRUGS MARKET
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 6. BARGAINING POWER OF BUYERS
FIGURE 7. BARGAINING POWER OF SUPPLIERS
FIGURE 8. THREAT OF NEW ENTRANTS
FIGURE 9. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. RESTRAINTS AND DRIVERS: GLOBAL PAIN MANAGEMENT DRUGS MARKET
FIGURE 12. U.S. PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 13. CANADA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 14. MEXICO PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 15. UK PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 16. FRANCE PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 17. GERMANY PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 18. ITALY PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 19. SPAIN PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 20. REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 21. JAPAN PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 22. CHINA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 23. AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 24. SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 25. INDIA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 26. TAIWAN PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 27. REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 28. BRAZIL PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 29. SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 30. SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 31. REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)